Market value & growth:
This is a market valued at $2.0 billion in 2020 that is forecast to grow 4.0% per year to $2.45 billion by 2025. The pandemic did result in a shift to more telehealth services. Treatment programs generate $1.4 billion, while the medications market is worth $627 million.
Treatment center revenues are expected to grow 4.5% per year from 2021 to 2025, outpacing the growth of the autism drugs market, which is forecast to grow 3.0% per year (average annual rate).
The need for treatment:
The number of autistic children is rising in the United States, at a rate of 6.2% a year. The CDC now estimates that 1 in 54 children born in the U.S. are autistic. More treatment centers: The overwhelming majority of the largest for-profit treatment companies has increased the number of centers they operate, and their revenues, compared to 2017.
The Autism drug market:
Several medications (Risperdal, Concerta) are still used to treat people with Autism, and less costly generics have entered the market, resulting in lower total revenues. There is substantial R&D taking place to develop new and more effective drugs.
Health insurance coverage for Autism:
Insurance coverage for Autistic children has improved over the past four years, with 64% now covered (vs. Thirty-six percent in 2016). All fifty states now cover it.
Revenue estimates: The top nine for-profit chains are estimated to have posted 2019 revenues of $547 million.
Market Analysis and Insights:
The global attention deficit hyperactivity disorder market size is expected to reach USD 24.9 billion by 2025, based on a new report by Grand View Research, Inc., exhibiting a 6.4% CAGR during the forecast period. Increase in awareness regarding ADHD among patients, physicians, and other healthcare providers is likely to up demand for effective treatment, in turn, propelling market growth.
An increase in awareness about mental health among the general population and governments is expected to propel the ADHD market. The rising number of people suffering from a host of mental health disorders, including attention-deficit/hyperactivity disorder, has caught the attention of governments around the world, forcing them to take necessary steps to address this condition. In 2016, the U.S. Department of Health & Human Services awarded up to USD 54 million to the Substance Abuse and Mental Health Services Administration (SAMHSA) for the next four years to address the needs of individuals with serious mental illnesses.
Approval and commercialization of new drugs by market players are also expected to play a crucial role in driving market growth over the coming years. For instance, in August 2017, Shire launched FDA-approved MYDAYIS for the treatment of ADHD patients aged 13 and older.
03 CANCER TREATMENT PAIN
Cancer Pain Market Overview:
The global cancer pain market was valued at $6,197.8 million in 2020, and is estimated to reach $10,329.4 million by 2030, growing at a CAGR of 5.3% from 2021 to 2030.
Growth of the global cancer pain market is majorly driven by increase in prevalence of cancer; rise in geriatric population; increase in healthcare expenditure; and increase in investments in R&D activities by various healthcare companies. For instance, according to American Cancer Society, nearly 1.8 million new cancer cases were diagnosed and about 606,520 cancer deaths were observed in the U.S. in 2020.
According to the International Agency for Research on Cancer, in 2020, approximately 1,065,960 new cases were reported for colorectal cancer worldwide. The geriatric population is more vulnerable to several types of cancers, such as lung cancer, bladder cancer, renal cancer, melanoma, and others, due to aging effect and mutation in the gene. According to the National Cancer Institute, the median age for diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer. Furthermore, according to the Medicare and Medicaid Services, the National Health Expenditure (NHE) reached $3.8 trillion in 2019. The NHE increased by 4.6% in 2019 and accounted for 17.7% of the U.S. GDP. Surge in demand for monoclonal antibodies for the treatment of cancer boosts the growth of the cancer pain market.
However, adverse effect associated with the use of drugs employed in cancer pain management such as drug tolerance, drug dependence, urinary retention, sleep disorders, cognitive impairment, and others are expected to restrict the cancer pain market growth during the forecast period.
Post-Traumatic Stress Disorder Market Summary:
The global post-traumatic stress disorder therapeutics market expected to reach 106.8 million by 2026 with CAGR of 4.5% during the forecast period from 2018 to 2026. Antidepressants including SSRIs (Zoloft and Paxil) are among the first line of treatment for PTSD, dominated the global market in 2017 and projected to retain its dominance during the forecast period. North America dominated the PTSD therapeutics market with more than 50% of market share for the year 2017. Higher awareness about healthcare and treatment among the general population, and a better rate of self-reporting are some macro factors contributing to the dominance of North America in the global market. Post-traumatic stress disorder (PTSD) is a vastly prevalent disorder but a rarely recognized syndrome that is characterized by some serious reactions such as fear, helplessness, and horror. According to the Diagnostic and Statistical Manual of Mental Disorders, PTSD is categorized as acute if symptoms are within three months of the trauma, and chronic if symptoms occur between three to six months of the trauma.
Post-traumatic stress disorder is classified as anxiety disorder and symptoms of PTSD can develop either immediately following a traumatic event or during time following. The symptoms of PTSD comprise abnormal mood swings, avoidance of stressful incidents and so on. PTSD occurs at any age, irrespective of gender; however, the prevalence of PTSD is higher in women. As reported by PTSD United, an estimated one in every eight women develops PTSD in a lifetime, thus making females twice more likely than males. The prevalence of PTSD in the United States is 3.5%.
Growing prevalence of post-traumatic stress disorder is the chief factor driving global post-traumatic stress disorder drugs market. Increase in events such as wars, combats, and interpersonal violence has been a major contributor to the growing prevalence of PTSD. Factors such as growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.
05 ANXIETY DISORDER AND DEPRESSION
The Global Anxiety Disorder and Depression Treatment Market:
The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in recent years.
The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.
Rising demand for antidepressants due to minimum side effects associated with these medications and growing awareness levels amongst the consumers are contributing toward the growth. However, patent expiration of most drugs combined with the increasing rate of drug withdrawals and the introduction of generic variants on a large scale is expected to restrain the growth of the anxiety disorders and depression treatment market in the coming years.
Furthermore, the presence of favorable reimbursement policies in developed countries for medications, and therapies coupled with their high success rates are anticipated to drive the growth over the forecast period. Whereas the prohibitive cost associated with the use of these devices and therapies including anesthesia and hospital stay has engendered a shift in preference for drugs amongst patients.
Addiction Market Summary:
Substance abuse is a dangerous, long-term condition that only grows worse if left untreated. Drug abuse treatment aids persons suffering from substance abuse disorders in regaining hope and embarking on a path to long-term recovery. Everyone who has an addiction needs to detox to get alcohol and other substances out of their system. Treatment options are usually determined by several factors, including the type of substance used, the length and degree of use, the presence of an addiction disorder, and the repercussions of the disorder on the individual. A wide range of care with a specific treatment program and follow-up choices can be critical for a successful treatment.
Addiction, dependency, major bodily injury, psychological harm, or death can all result from the compulsive, excessive, and self-destructive use of habit-forming drugs or substances. The global Substance Abuse Treatment Market is being driven by factors such as improved patient awareness, a higher treatment-seeking rate, more government participation, and incentives to reduce substance misuse in all nations. The global Substance Abuse Treatment Market is categorized by treatment, such as alcohol addiction treatment, nicotine addiction treatment, and drug abuse treatment.
Substance abuse treatment includes treatment for alcoholism, drug dependence, and addiction, often known as substance abuse disorders, and rehabilitation. Aggression, impatience, and forgetfulness are some of the most typical signs of drug usage. Doctors and physicians advise patients who want to stop abusing substances to seek out community assistance as well as drugs that can help control urges and treat medical issues caused by substance addiction.